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uantitative Instruments for
redicting Risk . . . and Benefit*
ames E. Udelson, MD, FACC,
arry P. Selker, MD, MSPH
oston, Massachusetts
any studies have examined the information content that
an be garnered from noninvasive stress testing to inform
atient management. For exercise electrocardiography
ECG), optimal interpretation does not involve simply
hether ST segment depression is present. Recent literature
as examined factors such as post-exercise heart rate recov-
ry (1) and the percent of heart rate reserve achieved (2) as
rognostic factors. For stress myocardial perfusion imaging
MPI), numerous elements beyond the presence of a per-
usion defect are important, such as the extent and severity
f defects, lung uptake of tracer, and transient dilatation of
he ventricle (3). Weighting all of these elements for test
nterpretation and a management strategy is challenging for
he individual physician.
See page 722
One solution to this vexing problem is the use of “predictive
nstruments.” These tools use data from thousands of patients
ith known outcomes to construct models to predict the
robability of an outcome too complex for an individual
linician to accomplish (4). Clinicians tend to focus on familiar
lements of a test, such as ST-segment depression on exercise
CG (which may or may not contain the most powerful data),
nd are influenced by their recent cases, experience, and
nterpretation of the literature (5). Predictive instruments
heoretically overcome these limitations.
What constitutes a good predictive instrument? First, the
utcome prediction must be calibrated to actual outcomes.
his is accomplished by deriving the model in one dataset
nd applying the instrument to a separate validation dataset.
econd, any instrument should be portable to a setting
istinct from where it was developed (external validity).
inally, and perhaps most importantly, any predictive in-
trument must be acceptable to clinicians for actual use and
hould improve clinical care (6).
Perhaps the best-known predictive instrument is the
uke treadmill score (7), which incorporates exercise time,
ymptoms, and ECG changes to construct an outcome
rediction. The instrument has been shown to be portable,
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Divisions of Cardiology and Clinical Care Research, Department ofi
edicine, and the Institute for Clinical Research and Health Policy Studies,
ufts-New England Medical Center, Boston, Massachusetts.n that patients referred for stress MPI were appropriately
ategorized (8) spatially distinct from where it was devel-
ped. Limitations have been reported in applying the score
o older patients (9). This should not come as a total
urprise, because the score was developed in a cohort that
id not include a large number of elderly subjects (7). The
hrombolysis In Myocardial Infarction (TIMI) risk score
or assessing outcome risk in acute coronary syndromes is
nother example (10).
In this issue of the Journal, Hachamovitch et al. (11)
erive and validate an “adenosine prognostic score,” com-
ining multiple elements from pharmacologic stress MPI
nto an outcome prediction. Most studies examining stress
PI have focused on the perfusion data to demonstrate
rognostic value (3) and also have shown that the perfusion
ata have incremental prognostic value once simpler data
ave been taken into account (12). However, although the
valuation of “incremental value” tells us about information
ontent, that does not speak to risk prediction for individual
atients in terms of combining all of the testing elements
nd weighting them appropriately. This limitation is over-
ome by incorporation into a predictive instrument.
Pharmacologic stress responses have been challenging for
linicians to incorporate, as vasodilator stress is physiologi-
ally distinct from exercise (13). Blood pressure and heart
ate responses reflect in part direct vasodilator actions as
ell as reflex responses, incorporating the integrity of the
utonomic nervous system. The present study is the first to
se a large database with known patient outcomes to model
ll of the elements occurring during a pharmacologic stress
PI study into an outcome prediction. A complex model is
resented that lends itself to future incorporation into now
idely available software programs. Moreover, the authors
resent a simplified score that clinicians can incorporate for
mmediate use. These data extend what has been generally
n intuitive incorporation of risk stratification into a more
uantitative format.
REDICTING TREATMENT BENEFIT
nother very important feature in the article by Hachamo-
itch et al. (11), not highlighted enough in our opinion, is
he use of the same data to predict potential benefit from
evascularization. Of the voluminous literature on risk
tratification, virtually all studies report prediction of risk.
he usually unstated assumption is that higher risk patients
hould be referred for catheterization and revascularization,
n assumption that has not been rigorously tested.
Hachamovitch et al. (14) have recently reported that the
urvival benefit of revascularization in outpatients referred
or stress testing was evident only in patients with 12% of
he left ventricle ischemic on single-photon emission com-
uted tomography (SPECT) MPI. Moreover, the benefit
ncreased as the magnitude of ischemia increased, suggest-
ng that SPECT MPI data not only predicted natural
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March 1, 2005:730–2 Editorial Commentistory risk but also the potential benefit of revasculariza-
ion. The current study extends those observations to a large
roup of patients undergoing pharmacologic stress, who are
enerally older, more likely women, and at generally higher
isk than patients referred for exercise testing. The revascu-
arization term within the prognostic score indicates that the
rognostic score predicts a lower risk level when revascular-
zation is performed as a function of the magnitude of
otential ischemia.
The provision of quantitative data on outcome risk and
he benefit of a treatment strategy is an important advance
or noninvasive testing that has been developed in other
reas. Selker et al. (15) developed, validated, and prospec-
ively tested the “Thrombolytic Predictive Instrument,”
hich, in the setting of ST-segment elevation myocardial
nfarction, incorporates demographic data and the ECG
ndings to create a 30-day mortality prediction for patients
reated with or without thrombolytic therapy, along with
he probability of treatment complications. In a 1,197-
atient randomized controlled trial, the provision of predic-
ion of benefit increased the use of thrombolytic therapy and
ts use within 1 h for patients with inferior myocardial
nfarction, for women, and for hospitals without on-site
mergency department physicians (15). Thus, that instru-
ent was developed, validated, and tested for its effect on
linical care. The TIMI risk score appears to provide
uidance as to the potential benefit of platelet inhibitors in
cute coronary syndromes (10), on the basis of retrospective
pplication to clinical trials.
The next important step will be to determine whether the
denosine prognostic score has external validity in the
urrent therapeutic era, as a proportion of the patients in
his report were studied more than 10 years ago, before the
idespread use of statins and other contemporary preventive
nd interventional therapies. Moreover, patients were pre-
umably managed based on the treating physician’s assess-
ent of benefit, influenced in part by the imaging data.
hus, the differences in outcomes from the two therapies
ay reflect the astuteness of selection for revascularization
y the treating physicians at a very sophisticated cardiac
enter. In previous studies, Hachamovitch et al. (14) have
ttempted to correct for this selection bias through the use
f propensity analysis, although it does not appear that this
pproach was used in this dataset. Hence, the true impact of
evascularization may well be quantitatively different from
hat presented by the current model. It would be ideal,
hough challenging, to test the impact of the prognostic
core in a randomized controlled trial format, where patients
re randomized to have the full information provided to
heir clinicians, or not, with outcomes compared between
he two groups. If favorable impact on decision-making is
hown, that would be a major advance.
The Thrombolytic Predictive Instrument provides a
limpse of how a predictive model based on perfusion
maging could be used to guide revascularization decisions.
n fact, just as the weather forecaster’s predicted probabilityf rain is most helpful for the overcast day, previous
vidence (15) suggests that it is for the patient for whom the
ecision might be less clear, or the need for treatment less
bvious, for whom such decision support is most helpful. In
tudies examining patterns of referral to catheterization, it is
f interest that only approximately 60% of patients with
high-risk” MPI finding are referred to catheterization (16).
he likely explanation for this apparent paradox is that
linicians are taking into account factors such as diabetes,
enal function, age, and so on, and deciding that the risk of
roceeding with intervention are simply too high on the
asis of the inferred benefit. This qualitative judgment
ight be well informed by an instrument that can incorpo-
ate numerous complex elements of risk and benefit. A
otentially very important direction in this area would be to
ncorporate data on the risks of revascularization from
ources such as the National Heart, Lung, and Blood
nstitute registries (17) or the Northern New England
roup (18) so that a more comprehensive analysis of risk and
enefit given extensive demographic and clinical data can be
ruly assessed in a real-life manner, an exciting direction for
his field. In the future, we as a community will be dealing
ith patients presenting for consideration of revasculariza-
ion at a later age with more comorbidities than we have
ealt with in the past. Prediction tools that can incorporate
arge amounts of information, such as the risks predicted
rom noninvasive test results and the potential benefits and
isks of revascularization on the basis of clinical and demo-
raphic factors, would be uniquely important for physicians
n the future. The study by Hachamovitch et al. (11) is an
mportant step in that direction.
eprint requests and correspondence: Dr. James E. Udelson,
ufts-New England Medical Center, 750 Washington Street, Box
0, Boston, Massachusetts 02111. E-mail: JUdelson@tufts-nemc.
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